Upstream Bio, Inc. (NASDAQ:UPB) — Market Cap & Net Worth
Market Cap & Net Worth: Upstream Bio, Inc. (UPB)
Upstream Bio, Inc. (NASDAQ:UPB) has a market capitalization of $507.96 Million ($507.96 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12457 globally and #2923 in its home market, demonstrating a -2.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Upstream Bio, Inc.'s stock price $9.40 by its total outstanding shares 54038591 (54.04 Million). Analyse cash efficiency ratio of Upstream Bio, Inc. to see how efficiently the company converts income to cash.
Upstream Bio, Inc. Market Cap History: 2024 to 2026
Upstream Bio, Inc.'s market capitalization history from 2024 to 2026. Data shows change from $888.39 Million to $507.96 Million (-31.66% CAGR).
Index Memberships
Upstream Bio, Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #322 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1193 of 3165 |
Weight: Upstream Bio, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Upstream Bio, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Upstream Bio, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
374.85x
Upstream Bio, Inc.'s market cap is 374.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $888.39 Million | $2.37 Million | -$62.81 Million | 374.85x | N/A |
Competitor Companies of UPB by Market Capitalization
Companies near Upstream Bio, Inc. in the global market cap rankings as of May 4, 2026.
Key companies related to Upstream Bio, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Upstream Bio, Inc. Historical Marketcap From 2024 to 2026
Between 2024 and today, Upstream Bio, Inc.'s market cap moved from $888.39 Million to $ 507.96 Million, with a yearly change of -31.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $507.96 Million | -65.38% |
| 2025 | $1.47 Billion | +65.15% |
| 2024 | $888.39 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Upstream Bio, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $507.96 Million USD |
| MoneyControl | $507.96 Million USD |
| MarketWatch | $507.96 Million USD |
| marketcap.company | $507.96 Million USD |
| Reuters | $507.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporat… Read more